IC
Iain Cai
Biocytogen Pharmaceuticals Director
MA
Biocytogen focuses on the discovery of monoclonal, bispecific, TCR-mimic antibodies and bispecific antibody-drug conjugates (ADCs) using its proprietary fully human antibody RenMice platform and high-throughput in vivo screening. Founded in 2009, Biocytogen has established a pipeline of 12 immuno-oncology assets, including two assets in Phase II, two in Phase I, and five in the CMC stage. Eucure Biopharma is the wholly owned subsidiary of Biocytogen dedicating to the clinical development of those innovative biological drugs.
https://eucure.com/en.html
on LinkedIn
